From: Impact of antiretroviral treatment on height evolution of HIV infected children
N (%) or median [IQR] | All | Height-for-age z-score at ART initiation | p-value | |||
---|---|---|---|---|---|---|
<−3 SD | −3 to < − 2 SD | − 2 to < − 1 SD | ≥ − 1 SD | |||
All | 477 | 116 (24%) | 119 (25%) | 119 (25%) | 123 (26%) | Â |
Male | 206 (43%) | 56 (48%) | 55 (46%) | 43 (36%) | 52 (42%) | 0.25a |
Age (years) | 6.2 [1.8–9.6] | 7.7 [5.1–10.6] | 7.4 [3.9–9.9] | 5.6 [1.5–9.5] | 2.0 [0.8–6.5] | < 0.001b |
ART regimen |  |  |  |  |  | < 0.001a |
 Dual NRTI-based regimen | 41 (9%) | 1 (1%) | 5 (4%) | 15 (13%) | 20 (16%) |  |
 PI-based regimen | 57 (12%) | 5 (4%) | 8 (7%) | 16 (13%) | 28 (23%) |  |
 NNRTI-based regimen | 379 (79%) | 110 (95%) | 106 (89%) | 88 (74%) | 75 (61%) |  |
CD4 percentage | 9 [2–17] | 5 [1–11] | 4 [1–13] | 11 [4–18] | 16 [10–23] | < 0.001b |
HIV-RNA load (log10copies/mL) | 5.17 [4.69–5.67] | 5.16 [4.74–5.59] | 5.20 [4.66–5.62] | 5.13 [4.82–5.55] | 5.22 [4.41–5.89] | 0.98b |
CDC HIV classification stage |  |  |  |  |  | < 0.001a |
 N | 87 (18%) | 12 (10%) | 15 (13%) | 20 (17%) | 40 (33%) |  |
 A | 136 (28%) | 25 (22%) | 32 (27%) | 41 (34%) | 38 (31%) |  |
 B | 132 (28%) | 34 (29%) | 32 (27%) | 38 (32%) | 28 (23%) |  |
 C | 17 (26%) | 45 (39%) | 40 (33%) | 20 (17%) | 17 (23%) |  |
Weight-for-age z-score |  |  |  |  |  | < 0.001a |
  < −3 SD | 18 (4%) | 9 (8%) | 7 (6%) | 1 (1%) | 1 (1%) |  |
  − 3 to <−2 SD | 59 (12%) | 33 (28%) | 12 (10%) | 12 (10%) | 2 (2%) |  |
  − 2 to <−1 SD | 196 (41%) | 66 (57%) | 68 (57%) | 46 (39%) | 16 (13%) |  |
  ≥ 1 SD | 204 (43%) | 8 (7%) | 32 (27%) | 60 (50%) | 104 (84%) |  |
Weight-for-height z-score | Â | Â | Â | Â | Â | 0.72a |
  < −3 SD | 5 (1%) | 2 (2%) | 2 (2%) | 1 (1%) | – |  |
 – 3 to <−2 SD | 27 (6%) | 7 (6%) | 9 (7%) | 6 (5%) | 5 (4%) |  |
 – 2 to <−1 SD | 95 (20%) | 27 (23%) | 25 (21%) | 22 (18%) | 21 (17%) |  |
  ≥ −1 SD | 350 (73%) | 80 (69%) | 83 (70%) | 90 (76%) | 97 (79%) |  |